An overview on the treatments and prevention against COVID-19
Y Panahi, AM Gorabi, S Talaei, F Beiraghdar… - Virology Journal, 2023 - Springer
Background The coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …
Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …
Early outpatient treatment for Covid-19 with convalescent plasma
Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …
Clinical practice guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 convalescent plasma
Description: Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a
potential treatment of COVID-19. However, meta-analysis data and recommendations are …
potential treatment of COVID-19. However, meta-analysis data and recommendations are …
[HTML][HTML] Randomized controlled trial of early outpatient COVID-19 treatment with high-titer convalescent plasma
BACKGROUND: The efficacy of polyclonal high titer convalescent plasma to prevent serious
complications of COVID-19 in outpatients with recent onset of illness is uncertain …
complications of COVID-19 in outpatients with recent onset of illness is uncertain …
Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization
Understanding the mechanisms of antibody-mediated neutralization of SARS-CoV-2 is
critical in combating the COVID-19 pandemic. Based on previous reports of antibody …
critical in combating the COVID-19 pandemic. Based on previous reports of antibody …
Early antibody treatment, inflammation, and risk of post-COVID conditions
Post-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for
PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known …
PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known …
Struggling with Covid-19 in adult inborn errors of immunity patients: A case series of combination therapy and multiple lines of therapy for selected patients
P Bez, G D'ippolito, CM Deiana, R Finco Gambier… - Life, 2023 - mdpi.com
Background: The SARS-CoV-2 infection is now a part of the everyday lives of
immunocompromised patients, but the choice of treatment and the time of viral clearance …
immunocompromised patients, but the choice of treatment and the time of viral clearance …
Hyperimmune Plasma and Immunoglobulins against COVID-19: a narrative review
M Franchini, D Focosi - Life, 2024 - mdpi.com
Since late 2019, the new SARS-CoV-2 virus belonging to the Coronaviridae family has been
responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral …
responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral …
Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes
W Guo, Y Zheng, S Feng - Frontiers in Cellular and Infection …, 2023 - frontiersin.org
The Omicron variant of SARS-CoV-2 has rapidly become the dominant strain worldwide due
to its high transmissibility, although it appears to be less pathogenic than previous strains …
to its high transmissibility, although it appears to be less pathogenic than previous strains …